论文部分内容阅读
目的 探讨原发卵巢肿瘤MR早期动态增强表现与CD44v6基因表达的关系。方法 分析 64例病理检查证实的含有实质成分原发卵巢肿瘤的早期动态增强MR表现与CD44v6基因表达 ,CD44v6表达应用免疫组织化学技术检测。结果 卵巢良性肿瘤主要呈现Ⅲ型曲线 ( 13 /19) ,CD44v6基因表达阳性率低为 10 .5 2 % ( 2 /19)。恶性肿瘤主要呈现Ⅰ型曲线 ( 43 /4 5 ) ,CD44v6基因表达阳性率高为 46.67% ( 2 1/4 5 )。统计学有显著差异 (P <0 .0 5 )。结论 卵巢肿瘤MR早期动态增强表现与CD44v6基因表达相关 ,MR早期动态增强扫描有助于良恶性卵巢肿瘤诊断及预测预后
Objective To investigate the relationship between early dynamic enhancement of MR in primary ovarian tumors and CD44v6 gene expression. Methods 64 cases of pathologically confirmed primary ovarian tumors with early dynamic enhanced MR expression and CD44v6 gene expression, CD44v6 expression detected by immunohistochemistry. Results The benign ovarian tumors mainly showed type Ⅲ curve (13/19), while the positive rate of CD44v6 gene expression was 10.52% (2/19). The type Ⅰ curve (43/45) was predominant in malignant tumors, and the positive rate of CD44v6 gene expression was 46.67% (2 1/4 5). Statistical differences were significant (P <0.05). Conclusions Early dynamic enhancement of MR in ovarian tumors is related to the expression of CD44v6 gene. Early dynamic contrast-enhanced MR in diagnosis of ovarian tumors is helpful for the diagnosis and prognosis of benign and malignant ovarian tumors